Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial – EUROPEAN JOURNAL OF CANCER

Reck, M; Ciuleanu, TE; Schenker, M; Bordenave, S; Cobo, M; Juan-Vidal, O; Reinmuth, N; Richardet, E; Felip, E; Menezes, J; Cheng, Y; Mizutani, H; Zurawski, B; Alexandru, A; Carbone, DP; Lu, S; John, T; Aoyama, T; Grootendorst, DJ; Hu, N; Eccles, LJ; Paz-Ares, LG – 2024 – 10.1016/j.ejca.2024.114296